{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T02:56:20Z","timestamp":1789440980907,"version":"build-2803163510"},"reference-count":94,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.jaip.2020.10.009","type":"journal-article","created":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T13:11:57Z","timestamp":1602767517000},"page":"1107-1117.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["Cost-Effectiveness of Biologics for Allergic Diseases"],"prefix":"10.1016","volume":"9","author":[{"given":"Ann Chen","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne L.","family":"Fuhlbrigge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Acosta","family":"Robayo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Shaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2020.10.009_bib1","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1067\/mai.2003.49","article-title":"Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma","volume":"111","author":"Corren","year":"2003","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.10.009_bib2","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1398-9995.2004.00772.x","article-title":"Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE","volume":"60","author":"Humbert","year":"2005","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2020.10.009_bib3","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/BF00204626","article-title":"Can anti-IgE be used to treat allergy?","volume":"15","author":"Davis","year":"1993","journal-title":"Springer Semin Immunopathol"},{"key":"10.1016\/j.jaip.2020.10.009_bib4","first-page":"122","article-title":"Monoclonal antibodies specific for human IgE-producing B cells: a potential therapeutic for IgE-mediated allergic diseases","volume":"8","author":"Chang","year":"1990","journal-title":"Biotechnology (NY)"},{"key":"10.1016\/j.jaip.2020.10.009_bib5","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1159\/000235333","article-title":"New concepts of IgE regulation","volume":"94","author":"Heusser","year":"1991","journal-title":"Int Arch Allergy Appl Immunol"},{"key":"10.1016\/j.jaip.2020.10.009_bib6","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1164\/ajrccm.155.6.9196082","article-title":"The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects","volume":"155","author":"Fahy","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2020.10.009_bib7","doi-asserted-by":"crossref","first-page":"573","DOI":"10.7326\/0003-4819-154-9-201105030-00002","article-title":"Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial","volume":"154","author":"Hanania","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaip.2020.10.009_bib8","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1067\/mai.2001.117880","article-title":"Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma","volume":"108","author":"Busse","year":"2001","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.10.009_bib9","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1185\/0300799019117010","article-title":"Efficacy of omalizumab, an anti-immunoglobulin E antibody, in patients with allergic asthma at high risk of serious asthma-related morbidity and mortality","volume":"17","author":"Holgate","year":"2001","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jaip.2020.10.009_bib10","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1164\/rccm.200708-1264ED","article-title":"The demise of anti IL-5 for asthma, or not","volume":"176","author":"O\u2019Byrne","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2020.10.009_bib11","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1136\/thoraxjnl-2014-205581","article-title":"Characterisation of an OCS-dependent severe asthma population treated with mepolizumab","volume":"69","author":"Prazma","year":"2014","journal-title":"Thorax"},{"key":"10.1016\/j.jaip.2020.10.009_bib12","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1513\/AnnalsATS.201312-454OC","article-title":"Cluster analysis and characterization of response to mepolizumab: a step closer to personalized medicine for patients with severe asthma","volume":"11","author":"Ortega","year":"2014","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jaip.2020.10.009_bib13","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1016\/j.clinthera.2016.07.010","article-title":"Long-term efficacy and safety of mepolizumab in patients with severe eosinophilic asthma: a multi-center, open-label, phase IIIb study","volume":"38","author":"Lugogo","year":"2016","journal-title":"Clin Ther"},{"key":"10.1016\/j.jaip.2020.10.009_bib14","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2020.10.009_bib15","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJMoa0808991","article-title":"Mepolizumab and exacerbations of refractory eosinophilic asthma","volume":"360","author":"Haldar","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2020.10.009_bib16","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.anai.2020.06.041","article-title":"Clinical use of biologics for asthma treatment by allergy specialists: a questionnaire survey","volume":"125","author":"Kuruvilla","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2020.10.009_bib17","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2165\/00003495-200161020-00008","volume":"61","author":"Easthope","year":"2001","journal-title":"Omalizumab. Drugs"},{"key":"10.1016\/j.jaip.2020.10.009_bib18","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/j.rmed.2010.07.011","article-title":"Omalizumab-induced decrease of Fc\u03beRI expression in patients with severe allergic asthma","volume":"104","author":"Chanez","year":"2010","journal-title":"Respir Med"},{"key":"10.1016\/j.jaip.2020.10.009_bib19","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.4049\/jimmunol.158.3.1438","article-title":"Down-regulation of Fc(epsilon)RI expression on human basophils during in\u00a0vivo treatment of atopic patients with anti-IgE antibody","volume":"158","author":"MacGlashan","year":"1997","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jaip.2020.10.009_bib20","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1164\/ajrccm.155.6.9196083","article-title":"Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response","volume":"155","author":"Boulet","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2020.10.009_bib21","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1398-9995.2004.00550.x","article-title":"Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR","volume":"59","author":"Vignola","year":"2004","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2020.10.009_bib22","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1183\/09031936.02.00016502","article-title":"The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma","volume":"20","author":"Buhl","year":"2002","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2020.10.009_bib23","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1183\/09031936.02.00278102","article-title":"Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma","volume":"20","author":"Buhl","year":"2002","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2020.10.009_bib24","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1067\/mai.2003.54","article-title":"Omalizumab improves asthma-related quality of life in patients with severe allergic asthma","volume":"111","author":"Finn","year":"2003","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.10.009_bib25","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1365-2222.2004.1916.x","article-title":"Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma","volume":"34","author":"Holgate","year":"2004","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2020.10.009_bib26","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1159\/000334701","article-title":"Effects of adding omalizumab, an anti-immunoglobulin E antibody, on airway wall thickening in asthma","volume":"83","author":"Hoshino","year":"2012","journal-title":"Respiration"},{"key":"10.1016\/j.jaip.2020.10.009_bib27","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S1081-1206(10)62170-9","article-title":"Omalizumab is effective in the long-term control of severe allergic asthma","volume":"91","author":"Lanier","year":"2003","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2020.10.009_bib28","doi-asserted-by":"crossref","first-page":"319","DOI":"10.4168\/aair.2016.8.4.319","article-title":"Omalizumab improves quality of life and asthma control in Chinese patients with moderate to severe asthma: a randomized phase III study","volume":"8","author":"Li","year":"2016","journal-title":"Allergy Asthma Immunol Res"},{"key":"10.1016\/j.jaip.2020.10.009_bib29","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13223-020-00419-z","article-title":"Protocol for a double-blind, randomized controlled trial on the dose-related efficacy of omalizumab in multi-food oral immunotherapy","volume":"16","author":"Langlois","year":"2020","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.jaip.2020.10.009_bib30","doi-asserted-by":"crossref","first-page":"e455","DOI":"10.1097\/MJT.0000000000000912","article-title":"Efficacy and safety of omalizumab for chronic spontaneous urticaria: a systematic review and meta-analysis of randomized controlled trials","volume":"27","author":"Jia","year":"2020","journal-title":"Am J Ther"},{"key":"10.1016\/j.jaip.2020.10.009_bib31","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1001\/jamapediatrics.2019.4476","article-title":"Treatment effect of omalizumab on severe pediatric atopic dermatitis: the ADAPT randomized clinical trial","volume":"174","author":"Chan","year":"2019","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.jaip.2020.10.009_bib33","doi-asserted-by":"crossref","first-page":"3181","DOI":"10.2147\/DDDT.S214307","article-title":"Omalizumab for chronic spontaneous urticaria in \u201ccomplex\u201d patients: data from real-life clinical practice","volume":"13","author":"Vollono","year":"2019","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.jaip.2020.10.009_bib34","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/all.12815","article-title":"\u201cReal-life\u201d effectiveness studies of omalizumab in adult patients with severe allergic asthma: systematic review","volume":"71","author":"Abraham","year":"2016","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2020.10.009_bib35","first-page":"619","article-title":"Mepolizumab (Nucala) for severe eosinophilic asthma","volume":"41","author":"Choy","year":"2016","journal-title":"P\u00a0T"},{"key":"10.1016\/j.jaip.2020.10.009_bib36","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1067\/mai.2003.1382","article-title":"Anti-IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics","volume":"111","author":"Menzies-Gow","year":"2003","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.10.009_bib37","doi-asserted-by":"crossref","first-page":"4774","DOI":"10.2174\/092986709789909639","article-title":"Mepolizumab and eosinophil-mediated disease","volume":"16","author":"Walsh","year":"2009","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.jaip.2020.10.009_bib40","doi-asserted-by":"crossref","first-page":"e59872","DOI":"10.1371\/journal.pone.0059872","article-title":"Efficacy of anti-interleukin-5 therapy with\u00a0mepolizumab in patients with asthma: a meta-analysis of randomized placebo-controlled trials","volume":"8","author":"Liu","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jaip.2020.10.009_bib41","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1016\/S0140-6736(00)03496-6","article-title":"Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response","volume":"356","author":"Leckie","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2020.10.009_bib42","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1183\/09031936.03.00027302","article-title":"Monoclonal anti-interleukin-5 treatment suppresses eosinophil but not T-cell functions","volume":"21","author":"B\u00fcttner","year":"2003","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2020.10.009_bib43","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1164\/rccm.200208-789OC","article-title":"Eosinophil\u2019s role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway","volume":"167","author":"Flood-Page","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2020.10.009_bib44","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1164\/rccm.200701-085OC","article-title":"A\u00a0study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma","volume":"176","author":"Flood-Page","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2020.10.009_bib45","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1056\/NEJMoa0805435","article-title":"Mepolizumab for prednisone-dependent asthma with sputum eosinophilia","volume":"360","author":"Nair","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2020.10.009_bib46","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1586\/eci.11.27","article-title":"Mepolizumab in eosinophilic disorders","volume":"7","author":"Abonia","year":"2011","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.jaip.2020.10.009_bib48","author":"Rokkas"},{"key":"10.1016\/j.jaip.2020.10.009_bib49","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1136\/gut.2009.178558","article-title":"Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial","volume":"59","author":"Straumann","year":"2010","journal-title":"Gut"},{"key":"10.1016\/j.jaip.2020.10.009_bib50","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/j.jaci.2006.09.007","article-title":"Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis","volume":"118","author":"Stein","year":"2006","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.10.009_bib51","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jaci.2003.10.049","article-title":"Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes","volume":"113","author":"Garrett","year":"2004","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.10.009_bib52","first-page":"564","article-title":"Reslizumab (Cinqair): an interleukin-5 antagonist for severe asthma of the eosinophilic phenotype","volume":"42","author":"Hom","year":"2017","journal-title":"P\u00a0T"},{"key":"10.1016\/j.jaip.2020.10.009_bib53","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jaci.2011.11.044","article-title":"Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial","volume":"129","author":"Spergel","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.10.009_bib54","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1053\/j.gastro.2014.04.019","article-title":"Efficacy, dose reduction, and resistance to high-dose fluticasone in patients with eosinophilic esophagitis","volume":"147","author":"Butz","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaip.2020.10.009_bib57","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.jaip.2019.09.036","article-title":"Efficacy of intravenous reslizumab in oral corticosteroid-dependent asthma","volume":"8","author":"Nair","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2020.10.009_bib58","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1164\/rccm.201103-0396OC","article-title":"Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study","volume":"184","author":"Castro","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2020.10.009_bib59","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-2600(15)00042-9","article-title":"Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials","volume":"3","author":"Castro","year":"2015","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2020.10.009_bib60","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.chest.2016.03.018","article-title":"Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts","volume":"150","author":"Corren","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2020.10.009_bib63","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13223-020-00424-2","article-title":"In patients with severe asthma with eosinophilia in reslizumab clinical trials, high peripheral blood eosinophil levels are associated with low FEV1 reversibility","volume":"16","author":"Virchow","year":"2020","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.jaip.2020.10.009_bib65","doi-asserted-by":"crossref","first-page":"84","DOI":"10.18176\/jiaci.0385","article-title":"Benralizumab: a new approach for the treatment of severe eosinophilic asthma","volume":"29","author":"D\u00e1vila Gonz\u00e1lez","year":"2019","journal-title":"J\u00a0Investig Allergol Clin Immunol"},{"key":"10.1016\/j.jaip.2020.10.009_bib67","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s12016-019-08775-4","article-title":"Targeted anti-IL-5 therapies and future therapeutics for hypereosinophilic syndrome and rare eosinophilic conditions","volume":"59","author":"Harish","year":"2020","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jaip.2020.10.009_bib68","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3389\/fmed.2018.00049","article-title":"Targeting the interleukin-5 pathway for treatment of eosinophilic conditions other than asthma","volume":"5","author":"Roufosse","year":"2018","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jaip.2020.10.009_bib69","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1053\/j.gastro.2020.02.038","article-title":"AGA Institute and the Joint Task Force on Allergy-Immunology Practice Parameters Clinical Guidelines for the Management of Eosinophilic Esophagitis","volume":"158","author":"Hirano","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaip.2020.10.009_bib70","first-page":"532","article-title":"Dupilumab (Dupixent): an interleukin-4 receptor antagonist for atopic dermatitis","volume":"43","author":"D\u2019Ippolito","year":"2018","journal-title":"P\u00a0T"},{"key":"10.1016\/j.jaip.2020.10.009_bib71","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1053\/j.gastro.2019.09.042","article-title":"Efficacy of dupilumab in a phase 2 randomized trial of adults with active eosinophilic esophagitis","volume":"158","author":"Hirano","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaip.2020.10.009_bib73","author":"Safire"},{"key":"10.1016\/j.jaip.2020.10.009_bib75","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.anai.2020.03.009","article-title":"Making the GRADE in anaphylaxis management: toward recommendations integrating values, preferences, context, and shared decision making","volume":"124","author":"Shaker","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2020.10.009_bib77","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.anai.2020.04.007","article-title":"Achieving the Quadruple Aim to deliver value-based allergy care in an ever-evolving health care system","volume":"125","author":"Iglesia","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2020.10.009_bib78","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMp1011024","article-title":"What is value in health care?","volume":"363","author":"Porter","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2020.10.009_bib79","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.anai.2020.01.029","article-title":"Engaging patient partners in state of the art allergy care: finding balance when discussing risk","volume":"125","author":"Shaker","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2020.10.009_bib80","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.anai.2018.08.019","article-title":"Shared decision making for the allergist","volume":"122","author":"Blaiss","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2020.10.009_bib81","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.anai.2019.05.012","article-title":"A\u00a0primer on cost-effectiveness in the allergy clinic","volume":"123","author":"Shaker","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2020.10.009_bib82","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/jama.2016.12195","article-title":"Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: Second Panel on Cost-Effectiveness in Health and Medicine","volume":"316","author":"Sanders","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jaip.2020.10.009_bib83","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1001\/jama.2018.6072","article-title":"QALYs in 2018\u2014advantages and concerns","volume":"319","author":"Neumann","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.jaip.2020.10.009_bib84","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1177\/0272989X13482524","article-title":"US valuation of the SF-6D","volume":"33","author":"Craig","year":"2013","journal-title":"Med Decis Making"},{"key":"10.1016\/j.jaip.2020.10.009_bib85","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.jaip.2018.11.043","article-title":"Health utility scores of atopic dermatitis in US adults","volume":"7","author":"Silverberg","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2020.10.009_bib86","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.anai.2019.05.015","article-title":"Providing cost-effective care for food allergy","volume":"123","author":"Shaker","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2020.10.009_bib87","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold","volume":"371","author":"Neumann","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2020.10.009_bib88","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/03007995.2019.1660539","article-title":"Cost-effectiveness of omalizumab for the treatment of moderate-to-severe uncontrolled allergic asthma in the United States","volume":"36","author":"Sullivan","year":"2020","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jaip.2020.10.009_bib89","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1007\/s40273-018-0658-x","article-title":"Cost-effectiveness of biological asthma treatments: a systematic review and recommendations for future economic evaluations","volume":"36","author":"McQueen","year":"2018","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jaip.2020.10.009_bib93","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.anai.2016.10.028","article-title":"Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis","volume":"118","author":"Whittington","year":"2017","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2020.10.009_bib94","article-title":"P15 Cost effectiveness of mepolizumab for severe eosinophilic asthma from the UK\u00a0perspective","volume":"72","author":"Doyle","year":"2017","journal-title":"Thorax"},{"key":"10.1016\/j.jaip.2020.10.009_bib95","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1080\/02770903.2018.1500584","article-title":"A\u00a0cost-effectiveness analysis of reslizumab in the treatment of poorly controlled eosinophilic asthma","volume":"56","author":"Lam","year":"2019","journal-title":"J\u00a0Asthma"},{"key":"10.1016\/j.jaip.2020.10.009_bib96","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1080\/03007995.2019.1605159","article-title":"Cost-utility analysis of reslizumab for patients with severe eosinophilic asthma inadequately controlled with high-dose inhaled corticosteroids and long-acting \u03b22-agonists in South Korea","volume":"35","author":"Han","year":"2019","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jaip.2020.10.009_bib98","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S2213-2600(18)30406-5","article-title":"Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial","volume":"7","author":"Busse","year":"2019","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2020.10.009_bib99","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.anai.2019.02.016","article-title":"Rapid onset of effect of benralizumab on morning peak expiratory flow in severe, uncontrolled asthma","volume":"122","author":"Chupp","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2020.10.009_bib100","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/cpt.1371","article-title":"Relationship between benralizumab exposure and efficacy for patients with severe eosinophilic asthma","volume":"106","author":"Chia","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jaip.2020.10.009_bib102","first-page":"877","article-title":"Cost effectiveness of benralizumab for severe, uncontrolled oral corticosteroid\u2013dependent asthma in Sweden","volume":"23","author":"Andersson","year":"2020","journal-title":"J\u00a0Med Econ"},{"key":"10.1016\/j.jaip.2020.10.009_bib103","first-page":"750","article-title":"Economic evaluation of dupilumab for moderate-to-severe atopic dermatitis: a cost-utility analysis","volume":"17","author":"Zimmermann","year":"2018","journal-title":"J\u00a0Drugs Dermatol"},{"key":"10.1016\/j.jaip.2020.10.009_bib104","doi-asserted-by":"crossref","first-page":"E26","DOI":"10.1002\/lary.28648","article-title":"Cost utility analysis of dupilumab versus endoscopic sinus surgery for chronic rhinosinusitis with nasal polyps","volume":"131","author":"Scangas","year":"2021","journal-title":"Laryngoscope"},{"key":"10.1016\/j.jaip.2020.10.009_bib105","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.jaci.2007.09.032","article-title":"American Academy of Allergy, Asthma & Immunology\/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis","volume":"120","author":"Cox","year":"2007","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.10.009_bib106","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.jaci.2011.04.010","article-title":"American Academy of Allergy, Asthma & Immunology\/American College of Allergy, Asthma & Immunology Omalizumab-Associated Anaphylaxis Joint Task Force follow-up report","volume":"128","author":"Cox","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.10.009_bib107","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jaip.2019.09.037","article-title":"Estimation of health and economic benefits of clinic versus home administration of omalizumab and mepolizumab","volume":"8","author":"Shaker","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2020.10.009_bibE1","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.jaci.2017.05.044","article-title":"Reduced need for surgery in severe nasal polyposis with mepolizumab: randomized trial","volume":"140","author":"Bachert","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.10.009_bibE5","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.anai.2019.05.012","article-title":"A\u00a0primer on cost-effectiveness in the allergy clinic","volume":"123","author":"Shaker","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2020.10.009_bibE6","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/jama.2016.12195","article-title":"Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: Second Panel on Cost-Effectiveness in Health and Medicine","volume":"316","author":"Sanders","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jaip.2020.10.009_bibE7","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.anai.2020.01.029","article-title":"Engaging patient partners in state of the art allergy care: finding balance when discussing risk","volume":"125","author":"Shaker","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2020.10.009_bibE8","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1001\/jama.2018.6072","article-title":"QALYs in 2018\u2014advantages and concerns","volume":"319","author":"Neumann","year":"2018","journal-title":"JAMA"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219820311193?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219820311193?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:28:02Z","timestamp":1761974882000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219820311193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":94,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S2213219820311193"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2020.10.009","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-Effectiveness of Biologics for Allergic Diseases","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2020.10.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}